Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma

Chinese Journal of Cancer

Volumn 28, Issue 1, 2009, Pages 76-78

  Luo, Yao Ling ^a,b   Ou, Guo Ping ^a,b   Chi, Pei Dong ^a,b   Liang, Yong Neng ^a,b   Liu, Yu Hui ^a,b   Huang, Ma Yan ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diagnosis; EBV DNase antibody; Epstein Barr virus DNA; Nasopharyngeal neoplasm; Real time fluorescence quantitative PCR

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; VIRUS ANTIBODY; IMMUNOGLOBULIN A; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; IMMUNOLOGY; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; VIROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY;

EID: 69849101023     PISSN: 1000467X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Zeng MS, Li DJ, Liu QL, et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient [J]. J Virol, 2005,79(24):15323-15330.
2. Cheng WM, Chan KH, Chen HL, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum [J]. Int J Cancer, 2002,97(4):489-492.
3. Zhang CQ, Zong YS, Huang BZ, et al. Enhancing the efficieney of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma [J]. Zhong Hua Zhong Liu Za Zhi, 2002,24(4):356-359.
4. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr Viral DNA in serum of patient with nasopharyngeal carcinoma [J]. Clin Cancer Res, 1998,4(3):665-669.
5. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma [J]. Cancer Res, 1999,59(6):1188-1191.
6. Gu MF, Li JJ, Chen XL, et al. Correlation between the specific DNase antibody level and TNM of the "92 staging method" for nasopharyngeal carcinoma [J]. Guang Dong Yi Xue Za Zhi, 2006,27(10):1470-1471.
7. Liao Y, Luo ZQ. The diagnostic value of quantitative analysis of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma [J]. Zhong Guo Er Bi Yan Hou Lu Di Wai Ke Za Zhi, 2007,13(3):186-188.
8. Zhang Y, Gao HY, Feng HX, et al. Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma [J]. Zhong Hua Yi Xue Za Zhi, 2004,84(12):982-986.
9. Li ZQ, Wang QP, Tian YQ, et al. Changes of serum Epstein-Barr virus-specific DNaes antibody level in pre-and postradiotherapy nasopharyngeal carcinoma patients [J].Yi Xue Yan Jiu Sheng Xue Bao, 2001,14(5):406-408.
10. Chen HF, Huang D. An Approach to the Method for Detecting the Titers of Antibody Against Epstein-Barr Virus Specific DNase in Sera from Patients with Naspharyngeal Carcinoma [J]. Sheng Wu Hua Xue Za Zhi, 1989,5(2):131-135.
11. Hou X, Zhang L, Zhao C, et al. Prognostic Impact of Plasma Epstein-Barr Virus DNA Concentration on Distant Metastasis in Nasopharyngeal Carcinoma [J]. Ai Zheng, 2006,25(7):785-792.
12. Peng PJ, Zhao C, Liao H, et al. Correlation between the Kinetics of Plasma EBV DNA Levels and Clinical Response During Treatment In Patient with Nasopharyngeal Carcinoma [J]. Ai Zheng, 2002,21(8):817-822.